Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients

Summary

This study aims to investigate the potential improvement in muscle function, compared to the placebo group, through the concurrent administration of denosumab and alfacalcidol over a one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65 and older. The study is planned as a double-blinded randomized controlled trial, intending to recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5 or more compared to the control group.

Timeline

Start

2024-02-13

Primary completion

2025-09-01

Completion

2025-09-01

Drugs

Indications